THERAPY DOSSIER · th-bd51622f320c

miR-34a-5p antagomir

Other

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 28668331 ↗2017Reported benefit

Total abdominal irradiation exposure impairs cognitive function involving miR-34a-5p/BDNF axis.

MouseRadiationC57BL/6JFemalen = n=18 or 12 per group for Morris water maze, n=12 per group…Tail vein (intravenous) injection0.5 uM antagomir dissolved in 100 ul DEPC waterImmediately after total abdominal irradiation

Model: Total abdominal irradiation with a single 10 Gy dose of gamma rays at 1.0 Gy/min (Gammacell 40 Exactor), causing distant cognitive impairment

Tail vein miR-34a-5p antagomir prevented the irradiation-induced rise in miR-34a-5p in blood and hippocampus, restored hippocampal Bdnf expression and time in the target quadrant, reduced faecal LCN2, and retained the irradiation-shifted gut bacterial composition.

Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…